Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

NCT01683149 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Topotecan
DRUG: Sorafenib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]